首页> 美国卫生研究院文献>Molecular Cellular Proteomics : MCP >Sequential Multiplexed Analyte Quantification Using Peptide Immunoaffinity Enrichment Coupled to Mass Spectrometry
【2h】

Sequential Multiplexed Analyte Quantification Using Peptide Immunoaffinity Enrichment Coupled to Mass Spectrometry

机译:使用肽免疫亲和富集与质谱法相继进行多路分析物定量

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Peptide immunoaffinity enrichment coupled to selected reaction monitoring (SRM) mass spectrometry (immuno-SRM) has emerged as a technology with great potential for quantitative proteomic assays. One advantage over traditional immunoassays is the tremendous potential for concurrent quantification of multiple analytes from a given sample (i.e. multiplex analysis). We sought to explore the capacity of the immuno-SRM technique for analyzing large numbers of analytes by evaluating the multiplex capabilities and demonstrating the sequential analysis of groups of peptides from a single sample. To evaluate multiplex analysis, immuno-SRM assays were arranged in groups of 10, 20, 30, 40, and 50 peptides using a common set of reagents. The multiplex immuno-SRM assays were used to measure synthetic peptides added to plasma covering several orders of magnitude concentration. Measurements made in large multiplex groups were highly correlated (r2 ≥ 0.98) and featured good agreement (bias ≤ 1%) compared with single-plex assays or a 10-plex configuration. The ability to sequentially enrich sets of analyte peptides was demonstrated by enriching groups of 10 peptides from a plasma sample in a sequential fashion. The data show good agreement (bias ≤ 1.5%) and similar reproducibility regardless of enrichment order. These significant advancements demonstrate the utility of immuno-SRM for analyzing large numbers of analytes, such as in large biomarker verification experiments or in pathway-based targeted analysis.
机译:肽免疫亲和富集与选择性反应监测(SRM)质谱(immuno-SRM)结合已成为一项具有定量蛋白质组学分析潜力的技术。相对于传统免疫测定法的一个优势是同时定量给定样品中多种分析物的巨大潜力(即多重分析)。我们试图通过评估多重分析能力并证明对单个样品中的肽类进行顺序分析来探索免疫SRM技术分析大量分析物的能力。为了评估多重分析,使用一套通用的试剂将免疫-SRM分析法分为10、20、30、40和50个肽组。多重免疫SRM分析法用于测量添加到血浆中的合成肽,覆盖了几个数量级的浓度。与单重分析或10重配置相比,大型多重组中的测量值高度相关(r 2 ≥0.98),并且具有良好的一致性(偏差≤1%)。通过以顺序方式富集血浆样品中的10种肽组,证明了顺序富集分析物肽组的能力。数据显示了良好的一致性(偏差≤1.5%)和相似的重现性,而与富集顺序无关。这些重大进展证明了免疫SRM在大量生物标志物验证实验或基于途径的靶向分析中用于分析大量分析物的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号